FI962980A0 - Muunnetut oligonukleotidit - Google Patents

Muunnetut oligonukleotidit

Info

Publication number
FI962980A0
FI962980A0 FI962980A FI962980A FI962980A0 FI 962980 A0 FI962980 A0 FI 962980A0 FI 962980 A FI962980 A FI 962980A FI 962980 A FI962980 A FI 962980A FI 962980 A0 FI962980 A0 FI 962980A0
Authority
FI
Finland
Prior art keywords
pct
nucleotides
sec
modified oligonucleotides
date
Prior art date
Application number
FI962980A
Other languages
English (en)
Swedish (sv)
Other versions
FI962980A (fi
FI116677B (fi
Inventor
Mesmaeker Alain De
Adrian Waldner
Jacques Lebreton
Marc-Olivier Bevierre
Catherine Lesueur
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9401446A external-priority patent/GB9401446D0/en
Priority claimed from GB9412526A external-priority patent/GB9412526D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI962980A0 publication Critical patent/FI962980A0/fi
Publication of FI962980A publication Critical patent/FI962980A/fi
Application granted granted Critical
Publication of FI116677B publication Critical patent/FI116677B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
FI962980A 1994-01-26 1996-07-26 Muunnetut oligonukleotidit, jotka ovat resistenttejä nukleaaseille ja kykenevät voimakkaaseen hydridisaatioon kohde-RNA:n tai -DNA:n kanssa FI116677B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9401446 1994-01-26
GB9401446A GB9401446D0 (en) 1994-01-26 1994-01-26 Modified oligonucleotides
GB9412526 1994-06-22
GB9412526A GB9412526D0 (en) 1994-06-22 1994-06-22 Modified oligonucleotides
EP9500156 1995-01-17
PCT/EP1995/000156 WO1995020597A1 (en) 1994-01-26 1995-01-17 Modified oligonucleotides

Publications (3)

Publication Number Publication Date
FI962980A0 true FI962980A0 (fi) 1996-07-26
FI962980A FI962980A (fi) 1996-07-26
FI116677B FI116677B (fi) 2006-01-31

Family

ID=26304218

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962980A FI116677B (fi) 1994-01-26 1996-07-26 Muunnetut oligonukleotidit, jotka ovat resistenttejä nukleaaseille ja kykenevät voimakkaaseen hydridisaatioon kohde-RNA:n tai -DNA:n kanssa

Country Status (13)

Country Link
US (1) US6066447A (fi)
EP (1) EP0741741B1 (fi)
JP (1) JPH09508134A (fi)
AT (1) ATE222921T1 (fi)
AU (1) AU697134B2 (fi)
CA (1) CA2180727A1 (fi)
DE (1) DE69527942T2 (fi)
DK (1) DK0741741T3 (fi)
FI (1) FI116677B (fi)
HU (1) HU220423B (fi)
IL (1) IL112424A0 (fi)
NO (1) NO316902B1 (fi)
WO (1) WO1995020597A1 (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3746294B2 (ja) * 1993-12-13 2006-02-15 ザ、プロクター、エンド、ギャンブル、カンパニー 粘度安定な濃縮液体布帛柔軟組成物
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
WO1997014709A1 (en) * 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
US5808035A (en) * 1995-12-08 1998-09-15 Usher; David A. Protected nucleoside and method for its synthesis
AU3340797A (en) * 1996-06-28 1998-01-21 Novartis Ag Modified oligonucleotides
HRP980375A2 (en) 1997-07-03 1999-04-30 Argyrios Georgios Arvanitis Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
PL204628B1 (pl) 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
EP1450811B1 (en) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CA2471059C (en) 2001-12-20 2011-04-26 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
KR100649352B1 (ko) * 2005-04-30 2006-11-27 주식회사 하이닉스반도체 반도체소자의 제조 방법
US7820810B2 (en) 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
AR105540A1 (es) * 2015-07-30 2017-10-11 Raptor Pharmaceuticals Inc Inhibidores de fucosidasas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) * 1986-10-28 1990-09-19 The Johns Hopkins University Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
ATE269870T1 (de) * 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
BR9106729A (pt) * 1990-08-03 1993-07-20 Sterling Winthrop Inc Composto,processos para inibir a degradacao por nuclease de compostos e para estabilizar sequencias de nicleotideos ou oligonucleosideos,composicao utilizavel para inibir expressao de genes e processo para inibir expressao de genes em um mamifero necessitando de tal tratamento
CA2092002A1 (en) * 1990-09-20 1992-03-21 Mark Matteucci Modified internucleoside linkages

Also Published As

Publication number Publication date
AU1534795A (en) 1995-08-15
ATE222921T1 (de) 2002-09-15
DE69527942D1 (de) 2002-10-02
US6066447A (en) 2000-05-23
CA2180727A1 (en) 1995-08-03
NO963092L (no) 1996-09-16
NO963092D0 (no) 1996-07-24
FI962980A (fi) 1996-07-26
EP0741741B1 (en) 2002-08-28
WO1995020597A1 (en) 1995-08-03
FI116677B (fi) 2006-01-31
JPH09508134A (ja) 1997-08-19
HU220423B (hu) 2002-01-28
EP0741741A1 (en) 1996-11-13
IL112424A0 (en) 1995-03-30
DE69527942T2 (de) 2003-03-27
HUT75704A (en) 1997-05-28
HU9602040D0 (en) 1996-09-30
NO316902B1 (no) 2004-06-21
AU697134B2 (en) 1998-09-24
DK0741741T3 (da) 2002-12-23

Similar Documents

Publication Publication Date Title
ATE222921T1 (de) Modifizierte oligonukleotide
CA2202280A1 (en) Sugar modified nucleosides and their use for synthesis of oligonucleotides
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DK0712860T3 (da) Fremgangsmåde til oprensning og isolation af 2'-deoxy-2',2'-diflournukleosider
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
DE3854297D1 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
ES2061416T1 (es) Ribocimas modificadas.
FI913236A (fi) 9-purinylfosfonsyraderivat.
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
ATE53588T1 (de) Herstellung von cytosin-nukleosiden.
NZ332834A (en) Glycosaminoglycan-related carbohydrate derivatives ( 5 saccharide groups ) having 4 to 6 sulphate groups
DK630589D0 (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
FR2738827B1 (fr) Detection des enterobacteries
FI960486A (fi) Loislääkkeitä
DE69323191D1 (de) Wasserlösliche retinoide
AU2739797A (en) (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides
NO962848L (no) Monohydrat av (E)-2'-deoksy-2'-(fluormetylen)cytidin
DK0611373T3 (da) Oligo-2-desoxynukleotider og deres anvendelse som lægemidler med antiviral virkning.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 116677

Country of ref document: FI